Top Two Hot of the Day: Grupo Supervielle S.A. (NYSE:SUPV), Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Grupo Supervielle S.A. (NYSE:SUPV)

Grupo Supervielle S.A. (NYSE:SUPV) closed at $10.49 on the last trading session with an increase of 1.94%, whereas, it previously closed at $10.29. The company has a market capitalization of $689.3 Million. The company traded shares of 937706 on the trading day while its three month average volume stands at 670.71 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Grupo Supervielle S.A. (NYSE:SUPV) produced diluted EPS of 0.8. The EPS estimate for next year as estimated by analysts is at 1.19 while EPS for next quarter is estimated at 0.27. Earnings per Share growth for this year is reported at 48, while the analysts estimated the EPS growth for next year at 1.19% and Earnings growth for next 5 years stands at 1.2% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 15.3%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Grupo Supervielle S.A. (NYSE:SUPV) is at 13.19 while the forward p/e is at 8.8. The P/S or Price to Sales ratio of Grupo Supervielle S.A. (NYSE:SUPV) stands at 1.24 and Price to Book or P/B for the most recent quarter stands at 2.21. The Price to Free Cash Flow ratio or P/FCF is reported at 1.13. The quick ratio and the current ratio of Grupo Supervielle S.A. (NYSE:SUPV) are reported at 0 and 0 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Grupo Supervielle S.A. (NYSE:SUPV) stands at 2.4, 17.8 and 34.2 respectively

The trailing twelve month Revenue of Grupo Supervielle S.A. (NYSE:SUPV) is reported at 556.3 Million with income of 72.6 Million. The outstanding shares of Grupo Supervielle S.A. (NYSE:SUPV) are 65.71 Million. The institutional Ownership of the shares of 36 stands at 0.80%, this figure is increased 2.12 in the last six months. The insider ownership for the shares of Grupo Supervielle S.A. (NYSE:SUPV) is ticked at 3.41%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Grupo Supervielle S.A. (NYSE:SUPV) is the Mean Target Price estimated by the analysts which stands at 12.63. The 52 week high of Grupo Supervielle S.A. (NYSE:SUPV) is placed at 33.37 and 52 week low is standing at 4.91.

Performance wise the shares of Grupo Supervielle S.A. (NYSE:SUPV) rose up 13.53% for the week, it also rise 20.85% for the monthly performance, while for the quarter it went down 31.45%. The shares decrease -22.35% for the half year and flew up for the Year-To-Date performance. The shares of Grupo Supervielle S.A. (NYSE:SUPV) shrinked -65.55% for the yearly performance.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) closed at $125.89 on the last trading session with an increase of 0.32%, whereas, it previously closed at $125.49. The company has a market capitalization of $7.52 Billion. The company traded shares of 949988 on the trading day while its three month average volume stands at 788.41 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) produced diluted EPS of 5.93. The EPS estimate for next year as estimated by analysts is at 13.98 while EPS for next quarter is estimated at 3.01. Earnings per Share growth for this year is reported at -15.4, while the analysts estimated the EPS growth for next year at 13.98% and Earnings growth for next 5 years stands at 14.73% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 4.6%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is at 21.24 while the forward p/e is at 9. The P/S or Price to Sales ratio of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands at 4.06 and Price to Book or P/B for the most recent quarter stands at 2.51. The Price to Free Cash Flow ratio or P/FCF is reported at 9.65. The quick ratio and the current ratio of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) are reported at 4.2 and 4.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands at 9.8, 18.2 and 9.8 respectively

The trailing twelve month Revenue of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is reported at 1.85 Billion with income of 364.7 Million. The outstanding shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) are 59.75 Million. The institutional Ownership of the shares of 97.3 stands at 0.80%, this figure is increased 1.25 in the last six months. The insider ownership for the shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is ticked at 2.6%, the figure is rose 0.15% in the last six months.

Some other important financial aspects to be discussed here for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is the Mean Target Price estimated by the analysts which stands at 176.89. The 52 week high of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is placed at 184.00 and 52 week low is standing at 113.52.

Performance wise the shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rose up 0.13% for the week, it also rise 1.56% for the monthly performance, while for the quarter it went up -17.91%. The shares decrease -27.26% for the half year and flew up for the Year-To-Date performance. The shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shrinked -16% for the yearly performance.